Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on LAVA Therapeutics (LVTX – Research Report), Acumen Pharmaceuticals (ABOS – Research Report) and Advanced Medical Solutions (GB:AMS – Research Report).
LAVA Therapeutics (LVTX)
Leerink Partners analyst Daina Graybosch maintained a Buy rating on LAVA Therapeutics on January 26 and set a price target of $11.00. The company’s shares closed last Tuesday at $3.12.
According to TipRanks.com, Graybosch is a 1-star analyst with an average return of
Currently, the analyst consensus on LAVA Therapeutics is a Strong Buy with an average price target of $6.00, implying a 73.4% upside from current levels. In a report issued on March 21, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Acumen Pharmaceuticals (ABOS)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Acumen Pharmaceuticals on January 26 and set a price target of $10.00. The company’s shares closed last Tuesday at $3.79.
According to TipRanks.com, Matteis is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acumen Pharmaceuticals with a $12.80 average price target, representing a 221.6% upside. In a report issued on March 27, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
Advanced Medical Solutions (GB:AMS)
In a report released yesterday, Christian Glennie from Stifel Nicolaus reiterated a Hold rating on Advanced Medical Solutions. The company’s shares closed yesterday at p187.40.
According to TipRanks.com, Glennie is ranked #8255 out of 8786 analysts.
Advanced Medical Solutions has an analyst consensus of Moderate Buy, with a price target consensus of p300.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LVTX:
- LAVA Therapeutics Announces Progress and Stability
- LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- Lava Therapeutics reports Q4 EPS (24c), consensus (12c)
- LVTX Upcoming Earnings Report: What to Expect?
- Lava Therapeutics announces clinical development milestone achieved by Pfizer
